Compare LEDS & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | PLUR |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | Taiwan | Israel |
| Employees | N/A | 113 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 12.8M |
| IPO Year | 2010 | 2026 |
| Metric | LEDS | PLUR |
|---|---|---|
| Price | $2.29 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.5K | ★ 15.1K |
| Earning Date | 11-27-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.12 | 31.46 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $43,009,000.00 | $1,016,000.00 |
| Revenue This Year | N/A | $902.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $120.69 | ★ N/A |
| Revenue Growth | ★ 729.81 | N/A |
| 52 Week Low | $1.01 | $0.85 |
| 52 Week High | $3.62 | $4.87 |
| Indicator | LEDS | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 33.68 |
| Support Level | $1.50 | $0.90 |
| Resistance Level | $2.47 | $1.85 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 9.58 | 37.59 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.